cobJan 3

Faut réduire la #securitesociale et fliquer les médecins qui prescrivent des arrêts maladies aux non-politiciens/miliardaires car ça coûte trop cher :

https://www.quechoisir.org/enquete-medicaments-braquage-pharmaceutique-n171088

Labo #MSD #Novartis

= pénurie de médicaments 'anciens' génériques/vieux brevêt cf #paracetamol

#sante #politique #economie #corruption #pembrolizumab #keytruda #monopole #zolgensma #vyndaqel #business

Prix des médicaments - Braquage pharmaceutique - Enquête

Les prix des nouveaux traitements sont devenus si exorbitants qu’ils mettent en péril l’accès aux soins. Illustration avec le numéro 1 des dépenses de santé en France, le Keytruda, un anticancéreux emblématique des dérives du système.

UFC-Que Choisir
Yonhap Infomax NewsNov 14
Alteogen Co. posted a 900% jump in Q3 revenue, driven by the commercialization of its ALT-B4 platform and milestone payments from FDA-approved Keytruda SC, marking a major turnaround in profitability and global expansion momentum.
#YonhapInfomax #Alteogen #ALTB4 #Q3Revenue #Keytruda #FDAApproval #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90913
Alteogen Posts 900% Surge in Q3 Revenue as ALT-B4 Commercialization Accelerates

Alteogen Co. posted a 900% jump in Q3 revenue, driven by the commercialization of its ALT-B4 platform and milestone payments from FDA-approved Keytruda SC, marking a major turnaround in profitability and global expansion momentum.

Yonhap Infomax
Tin hot mỗi ngàyNov 13

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu 

Trong vòng một thập niên, Keytruda (Pembrolizumab) của Merck đã tạo nên kỷ lục hiếm có: doanh thu vượt 146 tỷ USD, trở thành thuốc ung thư bán chạy nhất thế giới.

https://tinmoitrongngay2.wordpress.com/2025/11/13/%f0%9f%8c%bf-toan-canh-keytruda-thuoc-ung-thu-ban-chay-nh-at-the-gioi-2/

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu 

Trong vòng một th…

Tin mới trong ngày
Tin hot mỗi ngàyNov 13

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu 

Trong vòng một thập niên, Keytruda (Pembrolizumab) của Merck đã tạo nên kỷ lục hiếm có: doanh thu vượt 146 tỷ USD, trở thành thuốc ung thư bán chạy nhất thế giới.

https://tinmoitrongngay2.wordpress.com/2025/11/13/%f0%9f%8c%bf-toan-canh-keytruda-thuoc-ung-thu-ban-chay-nh-at-the-gioi/

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu 

Trong vòng một th…

Tin mới trong ngày
Yonhap Infomax NewsJun 4, 2025
Merus shares hit record highs after Phase 2 data showed strong survival rates for its head and neck cancer therapy, fueling Wall Street optimism and positive analyst outlooks.
#YonhapInfomax #Merus #Keytruda #Phase2Data #SurvivalRate #SharePrice #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=66099
Merus Gains Wall Street Optimism on Head and Neck Cancer Drug Prospects

Merus shares hit record highs after Phase 2 data showed strong survival rates for its head and neck cancer therapy, fueling Wall Street optimism and positive analyst outlooks.

Yonhap Infomax
Yonhap Infomax NewsJun 2, 2025
GI Innovation is set to sign South Korea’s first immuno-oncology technology licensing deal with Merck, potentially marking a milestone for the domestic biotech sector as talks near completion for GI-101 and GI-102 combination with Keytruda.
#YonhapInfomax #GIInnovation #Merck #ImmunoOncology #Keytruda #TechnologyTransfer #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=65767
GI Innovation Nears Major Licensing Deal With Pharma Giant Merck

GI Innovation is set to sign South Korea’s first immuno-oncology technology licensing deal with Merck, potentially marking a milestone for the domestic biotech sector as talks near completion for GI-101 and GI-102 combination with Keytruda.

Yonhap Infomax
Global News BCAug 9, 2024
B.C. woman fighting cancer denied immunotherapy drug due to trial period
Soledad Ronco struggled through chemotherapy while also receiving the immunotherapy drug Keytruda to keep the triple-negative breast cancer at bay.
#globalnews #Health #BCCancerAgency #Immunotherapy #Keytruda
https://globalnews.ca/news/10689293/bc-woman-cancer-denied-immunotherapy-drug/
B.C. woman fighting cancer denied immunotherapy drug due to trial period

Soledad Ronco struggled through chemotherapy while also receiving the immunotherapy drug Keytruda to keep the triple-negative breast cancer at bay.

Global News
Global NewsAug 9, 2024
B.C. woman fighting cancer denied immunotherapy drug due to trial period
Soledad Ronco struggled through chemotherapy while also receiving the immunotherapy drug Keytruda to keep the triple-negative breast cancer at bay.
#globalnews #Health #BCCancerAgency #Immunotherapy #Keytruda
https://globalnews.ca/news/10689293/bc-woman-cancer-denied-immunotherapy-drug/
B.C. woman fighting cancer denied immunotherapy drug due to trial period

Soledad Ronco struggled through chemotherapy while also receiving the immunotherapy drug Keytruda to keep the triple-negative breast cancer at bay.

Global News
Global News OkanaganAug 9, 2024
B.C. woman fighting cancer denied immunotherapy drug due to trial period
Soledad Ronco struggled through chemotherapy while also receiving the immunotherapy drug Keytruda to keep the triple-negative breast cancer at bay.
#globalnews #Health #BCCancerAgency #Immunotherapy #Keytruda
https://globalnews.ca/news/10689293/bc-woman-cancer-denied-immunotherapy-drug/
B.C. woman fighting cancer denied immunotherapy drug due to trial period

Soledad Ronco struggled through chemotherapy while also receiving the immunotherapy drug Keytruda to keep the triple-negative breast cancer at bay.

Global News
cafepharmaMay 9, 2024
Keytruda strikes out again in endometrial cancer with phase III flop—Novo inks $600M deal with Metaphore to develop next-gen obesity drugs —Takeda Pharma to restructure after annual profit slump --http://bit.ly/w28kSd #merck #keytruda #endometrialcancer #clinicaltrials #novonordisk #obesity #drugdevelopment #takeda #restructuring #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Cafepharma

Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more.

Cafepharma